International Journal of Innovative Technologies in Social Science
June 24, 2026
Aleksandra Łoś, Kacper Szkodziński, Inga Jakubczyk et al.
Depressive disorders affect up to 16% of the population over a lifetime and are a leading cause of disability. For 20–50% of patients, standard treatments fail, leading to treatment-resistant depression (TRD). A review of studies on psilocybin-assisted therapy (PAT) for major depressive disorder (MDD) and TRD found that PAT offers a faster onset of action than traditional antidepressants, with symptom reduction often occurring within the first week and lasting 6–12 months. Many patients also improved in anhedonia, anxiety, and psychosocial functioning. Psilocybin represents a promising alternative for severe depression and TRD, with rapid and lasting effects.
International Journal of Innovative Technologies in Social Science
June 24, 2026
Irmina Grygutis, Oskar Mikołajczyk, Kornelia Julia Fimiarz et al.
Ketamine and its derivative esketamine are rapid-acting treatments for treatment-resistant depression, but the best way to give them depends on balancing effectiveness, safety, cost, and available healthcare resources. Intravenous (IV) ketamine works fastest and most strongly but requires infusion equipment and monitoring for temporary high blood pressure and dissociation. FDA-approved intranasal esketamine has strong long-term data but needs supervised in-clinic administration and blood pressure checks. Oral and sublingual forms are easier and cheaper but less effective and carry higher risk of misuse. Subcutaneous and intramuscular injections offer high absorption with minimal setup but have little supporting evidence. The choice of route should be tailored to each patient's situation.
International Journal of Innovative Technologies in Social Science
June 15, 2026
Julia Osipowska, Marlena Kwolek, Alicja Judzińska et al.
Contemporary psychiatry faces stagnation by relying on daily-dose pharmacotherapy for chronic symptom management. Psychedelics and ketamine offer rapid-acting alternatives targeting underlying neurobiological mechanisms rather than mere symptom suppression. This multidisciplinary review synthesizes knowledge on 5-HT2A receptor agonism, next-generation non-hallucinogenic psychoplastogens, and ethical-legal challenges for global and Polish healthcare. It compares classic psychedelics with conventional treatments like SSRIs, examining socioeconomic factors affecting therapy democratization. The psychedelic renaissance requires a new psychiatric language rooted in neuroplasticity and connectivity. Scalability depends on isolating plasticity effects and using short-acting tryptamines to reduce clinical burdens. For Poland to participate, urgent legislative harmonization and ethical frameworks addressing patient suggestibility are needed.
International Journal of Innovative Technologies in Social Science
February 16, 2026
Esketamine nasal spray, the first novel mechanism treatment for treatment-resistant depression in decades, has an acceptable safety profile under clinical supervision. Common adverse effects such as dissociation and sedation resolve within two hours, and blood pressure elevations normalize within 1.5 hours without intervention. Pre-approval concerns about bladder cystitis, cognitive decline, and abuse were not confirmed: no cystitis occurred despite years of exposure, cognitive function remained stable or improved, and misuse was rare (less than 0.01%). Serious adverse events were infrequent (less than 0.2% of sessions), mainly during initial treatments. Mortality rates matched background rates in treatment-resistant depression. Long-term studies up to 6.5 years found no organ damage, cognitive decline, or meaningful abuse problems.
International Journal of Innovative Technologies in Social Science
January 28, 2026
Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.
Psilocybin-assisted therapy shows rapid, robust, and sustained antidepressant effects for major depressive disorder and treatment-resistant depression, often after one or two sessions. Its safety profile is generally favorable, with transient and mild adverse events. The therapy primarily acts on serotonin 5-HT2A receptors, modulating brain networks and enhancing neuroplasticity. However, high costs, limited accessibility due to the intensive therapeutic model, and regulatory hurdles present significant challenges. Compared with conventional antidepressants and ketamine, psilocybin offers a promising alternative, especially when standard treatments fail, by providing durable symptom reduction through unique neurobiological pathways.
International Journal of Innovative Technologies in Social Science
January 23, 2026
Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg et al.
Classical serotonergic hallucinogens like psilocybin and LSD are being re-evaluated in clinical research. A systematic review traces their history from indigenous use through prohibition to current trials. The compounds act via 5-HT2A receptor agonism and disrupt the Default Mode Network, which may help alleviate rigid cognitive patterns in depression and anxiety. Clinical data show significant therapeutic potential for Treatment-Resistant Depression, end-of-life distress, and substance use disorders. The review emphasizes that psychedelic-assisted therapy requires a specific psychotherapeutic framework, integration processes, and attention to cost-effectiveness and access equity. This approach suggests a shift from chronic symptom management to rapid, episodic curative interventions if regulatory and ethical challenges are addressed.
International Journal of Innovative Technologies in Social Science
December 24, 2025
Michal Gorski, Adam Januszkiewicz, Wiktoria Januszkiewicz et al.
About 3.9% of people worldwide experience Post Traumatic Stress Disorder (PTSD) in their lifetime, a condition marked by intrusive thoughts, hyperarousal, and avoidance after trauma. Standard treatments like psychotherapy and medication help only modestly for many, leaving chronic symptoms and related health problems. This narrative review synthesizes current knowledge on novel treatments, focusing on psychedelic drugs. It examines research on psychedelic therapy for PTSD, weighing benefits and drawbacks of different interventions, and asks what psychedelic-based pharmacological treatments exist or are emerging for PTSD patients and how they might be integrated into future clinical care. The review aims to offer practitioners and patients insights into the potential role of psychedelic compounds in PTSD treatment.
International Journal of Innovative Technologies in Social Science
September 30, 2025
Ignacy Rożek, Wojciech Gąska, Izabela Lekan et al.
Treatment-resistant depression affects many people with major depressive disorder who do not achieve remission with standard antidepressants. This review examines current and emerging strategies, including medication combinations, neuromodulation, and psychedelic-assisted therapies. Ketamine, esketamine, and psilocybin show promise for non-responders. Future approaches may repurpose drugs like lurasidone, pioglitazone, and minocycline for new mechanisms and better tolerability. A personalized, evidence-based, multidimensional treatment plan is emphasized to improve short-term response and long-term recovery.
International Journal of Innovative Technologies in Social Science
September 25, 2025
Mathias Spitaleri, Karol Kanon, Filip Kieloch et al.
Chronic pain is a widespread condition that often resists standard treatments like opioids, which carry risks of dependency and tolerance. Ketamine, a dissociative anesthetic, shows promise for managing several chronic pain types, including neuropathic pain, cancer-related pain, and complex regional pain syndrome. This review examines current evidence on ketamine's efficacy, mechanisms, clinical applications, safety, and limitations, drawing on articles from PubMed and Scopus.
International Journal of Innovative Technologies in Social Science
September 1, 2025
Anna Blazhkova, Magdalena Czaja, Hanna Sitka et al.
Psilocybin, combined with psychological support, shows significant antidepressant effects by enhancing neuroplasticity, brain connectivity, and cognitive flexibility. Evidence for treating major depressive disorder is well established, while initial findings for anorexia nervosa are promising but need more controlled trials. This review of 26 articles examines the substance's mechanism of action and clinical trial results, highlighting psilocybin as a novel treatment approach for both conditions.